Karyopharm Therapeutics

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Karyopharm reports robust revenue growth and strategic clinical advancements

Karyopharm Therapeutics demonstrated strong performance in revenue growth and clinical pipeline advancements, positioning them for continued success in 2023.
Strategic strengths in product portfolio, leadership, and innovation align well with opportunities in accelerating growth and exploring novel treatment approaches.
Challenges in differentiation, data updates, and dose optimization require focused strategies to overcome obstacles and drive sustainable growth.
Overall, Karyopharm's focus on patient outcomes, strategic expansion, and upcoming milestones indicate a positive trajectory for the company.

Karyopharm Therapeutics navigates revenue challenges while advancing pipeline innovations

Karyopharm Therapeutics faced revenue challenges due to PAP usage and discounts but showcased strong demand for XPOVIO and promising pipeline progress.
The company's financial stability was supported by expense reductions and total revenue of $38.7 million for Q1 2023.
Opportunities lie in commercial expansions, Phase III data advancements, and strategic product development efforts, positioning Karyopharm for future growth and innovation.

Karyopharm Therapeutics excels in Q2, eyes $2B peak revenues

Karyopharm Therapeutics showcased strong financial performance, strategic workforce reductions, and progress in pivotal Phase III trials during the Q2 earnings call. The company's focus on advancing novel SINE compounds and maintaining financial strength positions them well for future growth and value creation.

Karyopharm Therapeutics reports robust Q3 earnings and highlights growth prospects

Karyopharm Therapeutics showcased strong financial performance with revenue of $36 million and emphasized growth potential.
Promising Phase III trial data for myelofibrosis and endometrial cancer positions selinexor as a treatment paradigm changer.
Challenges include PAP impact from foundation closures, but opportunities lie in novel drug combinations and growth strategies.

Karyopharm meets revenue targets, eyes transformative outcomes in trials

Karyopharm Therapeutics delivered on revenue targets, showcasing strong performance and promising trial results in key indications.
While facing challenges in academic settings and financial obligations, the company's strategic strengths and growth opportunities position it well for the future.
With a focus on advancing Phase III trials, leveraging IP advantages, and exploring new treatment avenues, Karyopharm aims for continued innovation and market expansion.
Overall, Karyopharm's Q4 2023 Earnings Call reflects a balanced outlook with a solid foundation for growth and value creation in the biopharmaceutical sector.

Karyopharm Therapeutics reports strong Q1 performance and strategic refinancing

Karyopharm Therapeutics' Q1 2024 earnings call highlighted robust performance, strategic refinancing, and promising late-stage pipeline developments. While facing challenges in financial clarity and trial progress, the company is well-positioned to capitalize on growth opportunities through biomarker-driven patient selection and combination therapies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

- Formerly of Aravive, Genmab and Merck & Co., Dr. Rangwala will Lead Karyopharm's Clinical Development Programs and Strategy - - As Part of Karyopharm's Evolution, Co-Founders Dr. Shacham and Dr. Kauffman Will Transition Out of the Company on May 31, 2022 -  - Dr. Shacham Will Continue her Engagement with the Company's Scientific Advisory Board and Serve in an Advisory Capacity - NEWTON, Mass. , March 29, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Reshma Rangwala, MD, PhD, as the Company's Chief Medical Officer.

Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appointment of Reshma Rangwala, MD, PhD as Chief Medical Officer

Study Results to be Presented at the European Society of Medical Oncology's  Virtual Plenary and the Society for Gynecologic Oncology 2022 Annual Meeting on Women's Cancer Company to Host Investor Conference Call on March 17 th at 4:30 pm ET NEWTON, Mass. , March 16, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that results from the Phase 3 SIENDO study will be presented at the European Society of Medical Oncology's (ESMO) Virtual Plenary taking place on Thursday, March 17, 2022.

Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer

– Elhan Webb, CFA, Formerly of Rubius Therapeutics and Radius Health, Appointed as Senior Vice President of Investor Relations – – Webb Brings More than 20 Years of Diverse International Experience Across Investor Relations, Business Development, Investment Analysis and Portfolio Management in the Healthcare and Biotechnology Fields – NEWTON, Mass., March 14, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Elhan Webb as Senior Vice President of Investor Relations.

Karyopharm Names New Head of Investor Relations

NEWTON, Mass. , March 9, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Barclays Global Healthcare Conference.

Karyopharm to Participate at the Barclays Global Healthcare Conference

Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock plunged after an update on its supplemental New Drug Application submission based on the Phase 3 SIENDO study data of selinexor as front-line maintenance therapy following chemotherapy in advanced or recurrent endometrial cancer. The.

Why Are Karyopharm Shares Trading Lower Today

NEWTON, Mass., March 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its previously planned supplemental New Drug Application (sNDA) submission based on the data from the Phase 3 SIENDO study evaluating selinexor as a front-line maintenance therapy following chemotherapy in patients with advanced or recurrent endometrial cancer.

Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer

Investors aren't pleased with the surprise departure of the company's chief medical officer.

Here's Why Karyopharm Therapeutics Is Sliding on Tuesday

Karyopharm Therapeutics Inc (NASDAQ: KPTI) revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities." While CEO Paulson looks for Shah's replacement, he has recruited two Big Pharma vets to take up key.

Why Are Karyopharm Shares Plunging Today?

NEWTON, Mass., Feb. 22, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D.

Karyopharm Announces Changes to Its Clinical Leadership Team

Primary endpoint of phase 3 SIENDO study met in which a statistically significant improvement of progression-free survival was observed in patients treated with selinexor over placebo.

Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates

NEWTON, Mass., Feb. 11, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.

Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference

An analyst upgrade that followed much better-than-expected quarterly results put some real zip into the biotech's stock.

Why Karyopharm Therapeutics Stock Was a Winner on Wednesday

Karyopharm Therapeutics (KPTI) CEO, Richard Paulson on Q 2021 Results - Earnings Call Transcript

Fourth-quarter sales of Xpovio were encouraging, but top-line results from another trial were a little disappointing.

Why Karyopharm Therapeutics Stock Is Falling Today

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 215% and 125.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Tops Q4 Earnings and Revenue Estimates

NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line results from the Phase 3 S elinexor I n ENDO metrial Cancer (SIENDO/ENGOT-EN5/GOG-3055) study (n=263) evaluating the efficacy and safety of front-line maintenance therapy using selinexor, an oral medication, in patients with advanced or recurrent endometrial cancer.

Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer

Karyopharm (KPTI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Karyopharm (KPTI)

NEWTON, Mass., Feb. 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2021 financial results on Tuesday, February 8, 2022.

Karyopharm to Report Fourth Quarter and Full Year 2021 Financial Results on February 8, 2022

The FDA bestows an Orphan Drug status to Karyopharm's (KPTI) investigational candidate, eltanexor, for treating myelodysplastic syndromes.

Karyopharm's (KPTI) Eltanexor Gets Orphan Drug Tag for MDS

NEWTON, Mass., Jan. 24, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for eltanexor, a novel oral, Selective Inhibitor of Nuclear Export (SINE) compound, for the treatment of myelodysplastic syndromes (MDS).

Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes

NEWTON, Mass., Jan. 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present virtually at the B.

Karyopharm to Present at B. Riley Securities Oncology Investor Conference

NEWTON, Mass., Jan. 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Sohanya Cheng has been promoted to Chief Commercial Officer.

Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer

NEWTON, Mass., Jan. 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2021 net product revenue estimates for XPOVIO, the Company's first-in-class, oral XPO1 inhibitor, and outlined its 2021 achievements and 2022 objectives.

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives

NEWTON, Mass., Jan. 4, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present at the 40th Annual J.P.

News for Karyopharm Therapeutics Stock (KPTI)